Biotech VC dips in 3Q, but 2014 on track to beat 2013

US venture capital investment in private biotechnology companies dipped to $1.05bn in the third quarter from $1.84bn in the second quarter, but venture funding in 2014 remains on track to beat the 2013 total and may exceed $5bn for the year – a total that hasn't been reached since 2008.

More from Anticancer

More from Therapy Areas